Down Syndrome and Acute Myeloid Leukemia: The Paradox of Increased Risk for Leukemia and Heightened Sensitivity to Chemotherapy
- 15 September 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (18) , 3385-3387
- https://doi.org/10.1200/jco.2003.05.086
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children’s Cancer Group Study 2891Journal of Clinical Oncology, 2003
- GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndromeBlood, 2003
- Transient leukaemia – a benign form of leukaemia in newborn infants with trisomy 21British Journal of Haematology, 2003
- Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndromeNature Genetics, 2002
- Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experienceBlood, 2001
- Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 [see comments]Blood, 1992
- Leukemia in Down Syndrome: A ReviewPediatric Hematology and Oncology, 1992
- Prognosis of Down's syndrome with acute leukaemia.Archives of Disease in Childhood, 1990
- The Will Rogers PhenomenonNew England Journal of Medicine, 1985
- Down syndrome and acute leukemia in children: A 10-year retrospective survey from Childrens Cancer Study GroupThe Journal of Pediatrics, 1984